References
- B. Trombetta, 2005 Industry Audit, Pharmaceutical Executive, September 1, 2005; http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=177964
- M. Herper and P. Kang, World's 10 best-selling drugs, Forbes.com, March 28, 2006.
- S. Schweitzer, Pharmaceutical Economics and Policy, Oxford University Press, Oxford 2007, pp. 27-29.
- USGAO, Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process, US General Accountability Office, GAO-06-402, Washington (DC) 2006.
- Bain and Co., Has the pharmaceutical blockbuster model gone bust?, Brain & Company Press Release, December 8, 2003.
- B. L. Strom, How the US drug safety system should be changed, J. Am. Med. Assoc. 295 (2006) 2072-2074; DOI: 10.1001/jama.295.17.2072.
- US National Institute of Medicine, The Future of Drug Safety: Action Steps for Congress, US National Institute of Medicine, Washington (DC), 2006.
- T. Callr'eus, The precautionary principle and pharmaceutical risk management, Drug Safety 28 (2005) 465-471.
- M. Kremer, Pharmaceuticals and the developing world, J. Ec. Persp. 16 (2002) 67-90.
- F. Laforgia, F. Montobbio and L. Orsenigo, IPRs, technological and industrial development and growth: the case of the pharmaceutical industry, Centro di Ricerca sui Processi di Innovazione e Internazionalizzazione, Università Commerciale (CESPRI), WP n. 206, October 2007.
- J. Post, A. Lawrence and J. Weber, Business and Society: Corporate Strategy, Public Policy, Ethics, McGraw-Hill/Irwin, New York 2002.
- The Australian Concise Oxford Dictionary (Ed. B. Moore), 4th ed., Oxford University Press, South Melbourne (VIC) 2004.
- L. Newton, Ethics in America: Source Reader, Prentice-Hall, Upper Saddle River (NJ) 2004.
- L. Leape, Error in medicine, J. Am. Med. Assoc. 272 (1994) 1850-1862; DOI: 10.1001/jama.1994.03520230061039.